Three drugs were newly administered in HAH at the request of physicians and after agreement of HAH staff: belinostat for the treatment of relapsed or refractory peripheral T‐cell lymphoma after the first injection of each course in the outpatient clinic, durvalumab for non‐small cell lung cancer after at least one injection in the outpatient clinic and pertuzumab for HER2‐positive breast cancer after at least two injections received in the outpatient clinic to assess tolerance. Here, ERBB2 is linked to lung cancer.